FDA approves Johnson & Johnson’s nasal spray for depression

FDA Approves Nasal Spray for Depression
The nasal spray Spravato, which is made from the drug esketamine, had been approved in 2019 for patients who failed to respond to at least two oral antidepressants.
FDA approves Spravato, first monotherapy nasal spray to treat depression
The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression. Johnson & Johnson's Spravato was approved to treat a major depressive disorder,
J&J's ketamine-derived nasal spray approved by FDA to treat depression
Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those who had an inadequate response to oral antidepressants.
FDA approves Johnson & Johnson’s nasal spray for depression as stand-alone treatment
Spravato is now the first-ever stand-alone therapy for treatment-resistant depression, and is on its way to becoming a blockbuster product.
J&J's Spravato gets another lift with new FDA approval
The accelerating sales growth of Johnson & Johnson's Spravato could go up yet another gear after the FDA approved a third indication for the novel antidepressant.
FDA Approves Spravato Nasal Spray as a Standalone Treatment for Major Depressive Disorder
One-third of folks with major depressive disorder experience treatment-resistant depression (TRD), a condition that makes it more difficult to be treated by traditional oral antidepressants.
The FDA just approved this ketamine-derived nasal spray for depression treatment
The Food and Drug Administration (FDA) has approved Spravato, a nasal spray developed by Johnson & Johnson, as a standalone treatment for adults with major depressive disorder who have not responded to at least two other antidepressants.
FDA Approves Johnson & Johnson's Treatment As First Monotherapy For Treatment-Resistant Depression
FDA approves Johnson & Johnson's Spravato nasal spray as a monotherapy for major depressive disorder, showing superior efficacy in clinical trials.
FDA allows standalone use of nasal spray antidepressant Spravato (esketamine)
The FDA says esketamine, an antidepressant derived from the anesthetic and party drug ketamine, can now be prescribed on its own. It was approved in 2019 to treat severe depression.
J&J's Spravato Wins FDA Approval, Stands as a Game-Changer for Mental Health Care
New Brunswick, NJ January 21, 2025 Johnson & Johnson ( NYSE:JNJ) has finally got its breakthrough depression treatment, Spravato (esketamine), approved by the U.S. FDA (Food and Drug Administration) as thefirst and only standalone monotherapy for TRD (treatment-resistant depression).
FDA approves nasal spray drug to treat depression
Johnson & Johnson has announced that the U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray as the first and only monoth
Pharm Exec17h
FDA Approves Johnson & Johnson’s Spravato for Treatment-Resistant Depression
CIII nasal spray, marking the first monotherapy to be approved for adults with treatment-resistant depression (TRD).
WTEN13h
Magnetic stimulation for brain offering help for major depression
A non-invasive form of treatment for clinical depression is hoping to provide even faster results thanks to new research.